241 related articles for article (PubMed ID: 33677674)
61. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
[TBL] [Abstract][Full Text] [Related]
62. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
Nowak-Göttl U; Heinecke A; von Kries R; Nürnberger W; Münchow N; Junker R
Thromb Res; 2001 Aug; 103(3):165-72. PubMed ID: 11672578
[TBL] [Abstract][Full Text] [Related]
63. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
64. Antithrombin III as the Indicator of L-Asparaginase Activity in Children Treated for Acute Lymphoblastic Leukemia.
Czogała M; Balwierz W; Sztefko K; Rogatko I
J Pediatr Hematol Oncol; 2017 Mar; 39(2):114-120. PubMed ID: 28060110
[TBL] [Abstract][Full Text] [Related]
65. PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia
Rausch CR; Marini BL; Benitez LL; Elias A; Burke PW; Bixby D; Perissinotti AJ
Leuk Lymphoma; 2018 Mar; 59(3):617-624. PubMed ID: 28718698
[TBL] [Abstract][Full Text] [Related]
66. Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU.
Lebovic R; Pearce N; Lacey L; Xenakis J; Faircloth CB; Thompson P
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28436558
[TBL] [Abstract][Full Text] [Related]
67. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
[TBL] [Abstract][Full Text] [Related]
68. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.
Asselin BL; Kreissman S; Coppola DJ; Bernal SD; Leavitt PR; Gelber RD; Sallan SE; Cohen HJ
J Pediatr Hematol Oncol; 1999; 21(1):6-12. PubMed ID: 10029805
[TBL] [Abstract][Full Text] [Related]
69. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Bade NA; Lu C; Patzke CL; Baer MR; Duong VH; Law JY; Lee ST; Sausville EA; Zimrin AB; Duffy AP; Lawson J; Emadi A
J Oncol Pharm Pract; 2020 Jan; 26(1):74-92. PubMed ID: 30917738
[TBL] [Abstract][Full Text] [Related]
70. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
71. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
72. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
Schulte R; Hinson A; Huynh V; Breese EH; Pierro J; Rotz S; Mixon BA; McNeer JL; Burke MJ; Orgel E
Cancer Med; 2021 Nov; 10(21):7551-7560. PubMed ID: 34528411
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
74. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
[TBL] [Abstract][Full Text] [Related]
75. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
[TBL] [Abstract][Full Text] [Related]
76. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
[TBL] [Abstract][Full Text] [Related]
77. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children.
Nowak-Göttl U; Kuhn N; Wolff JE; Boos J; Kehrel B; Rath B; Jürgens H
Eur J Haematol; 1996; 56(1-2):35-8. PubMed ID: 8599991
[TBL] [Abstract][Full Text] [Related]
78. Pegaspargase-induced pancreatitis.
Alvarez OA; Zimmerman G
Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127
[TBL] [Abstract][Full Text] [Related]
79. Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy?
Tong WH
Br J Haematol; 2022 Apr; 197(2):e24-e25. PubMed ID: 34713438
[No Abstract] [Full Text] [Related]
80. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study.
Leone G; Gugliotta L; Mazzucconi MG; De Stefano V; Belmonte MM; Dragoni F; Specchia G; Centra A; Gamba G; Camera A
Thromb Haemost; 1993 Jan; 69(1):12-5. PubMed ID: 8446931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
